domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -79,10 +79,16 @@ Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
+*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16*
 
 BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plus manufacturer-funded lifestyle support represents the first major policy attempt to address the chronic-use cost structure. The Medicare GLP-1 Bridge (July 2026) provides immediate price relief while full model architecture is built, indicating urgency around cost containment.
 
+
+### Additional Evidence (challenge)
+*Source: [[2025-12-01-who-glp1-guidelines-behavioral-therapy-combination]] | Added: 2026-03-18*
+
+WHO's conditional recommendation structure and behavioral therapy requirement suggest the 'chronic use model' framing may be incomplete. The guideline establishes medication-plus-behavioral-therapy as the standard, not medication alone, which may have different economics than the pure pharmaceutical model. WHO also announced it will develop 'an evidence-based prioritization framework to identify which adults with obesity should be prioritized for GLP-1 treatment'—implying targeted use rather than universal chronic treatment.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -67,10 +67,16 @@ Digital behavioral support may partially solve the persistence problem: UK study
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
+*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16*
 
 BALANCE Model's manufacturer-funded lifestyle support requirement directly addresses the persistence problem by mandating evidence-based programs for GI side effects, nutrition, and physical activity—the factors most associated with discontinuation. This shifts the cost of adherence support from payers to manufacturers.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-12-01-who-glp1-guidelines-behavioral-therapy-combination]] | Added: 2026-03-18*
+
+WHO's conditional recommendation requiring behavioral therapy combination provides international regulatory support for adherence interventions. The guideline explicitly states GLP-1s should be 'combined with intensive behavioral therapy to maximize and sustain benefits'—directly addressing the persistence problem by making behavioral support the standard of care rather than an optional add-on.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.json

@@ -0,0 +1,26 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 3,
+    "rejected": 1,
+    "fixes_applied": [
+      "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination.md:set_created:2026-03-18",
+      "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d",
+      "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination.md:stripped_wiki_link:GLP-1 receptor agonists are the largest therapeutic category"
+    ],
+    "rejections": [
+      "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-18"
+}

inbox/archive/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.md

@@ -7,9 +7,13 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: guideline
-status: unprocessed
+status: enrichment
 priority: high
 tags: [who, glp-1, obesity, guidelines, behavioral-therapy, global-health, equity, access, semaglutide, tirzepatide, liraglutide]
+processed_by: vida
+processed_date: 2026-03-18
+enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -62,3 +66,10 @@ This is worth a separate archive from the basic WHO announcement because the beh
 PRIMARY CONNECTION: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox (March 12 claim candidate)
 WHY ARCHIVED: WHO formal guideline establishing behavioral therapy + GLP-1 as global standard of care — this changes the economic model analysis since behavioral support is now the baseline, not an add-on
 EXTRACTION HINT: The conditional recommendation structure and the behavioral therapy requirement are the extractable elements. The basic fact of WHO approving GLP-1s is in the existing archive; this archive is specifically about the standard-of-care implications.
+
+
+## Key Facts
+- WHO issued conditional recommendations for liraglutide, semaglutide, and tirzepatide in obesity treatment on 2025-12-01
+- WHO guideline was published simultaneously in JAMA
+- WHO will develop an evidence-based prioritization framework for GLP-1 treatment by 2026
+- Conditionality based on: limited long-term efficacy/safety data, current high costs, inadequate health-system preparedness, equity implications